1
|
Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhani-Hakemi M, Shimosaka A. Integral membrane protein expression of human CD25 on the cell surface of HEK293 cell line: the available cellular model of CD25 positive to facilitate in vitro developing assays. Biomol Concepts 2019; 10:150-159. [PMID: 31541599 DOI: 10.1515/bmc-2019-0018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 07/04/2019] [Indexed: 02/05/2023] Open
Abstract
Typically, CD25 is expressed on the cellular surface of regulatory T (Treg) cells. These cells are significant in regulating the self-tolerance and also preventing the immune system from attacking a person's own tissues and cells. They promote the cancer progression by playing an important role in evading the immune system. Thus, the experimental procedures was aimed to clone and express human CD25 in HEK293 cell line, as the available cellular model, for the purpose of developing assays to facilitate and enhance the studies on an available CD25 positive cell. The secondary RNA structure of CD25 was evaluated by in silico analysis. Then, cDNA of human CD25 were synthesized from isolated total mRNA of cultured and stimulated PBMCs from blood donors. After cloning the cDNA of CD25 into a pcDNA3.1(+) plasmid, using the effective transfection of the recombinant pcDNA3.1(+) in HEK293, qRT-PCR and flow cytometry methods were used to quantitatively evaluate CD25 transcripts and protein level. There was a 4.8 fold increase in transcripts and a 76.2% increase in protein levels of CD25 when comparing the transfected and control cell lines. The genetically engineered HEK293 cell line expressing Treg cell surface marker of CD25 was introduced in this study for the first time. This cell line can be used to overcome the problematic issues for studying Treg cells including low population of Tregs in peripheral blood, low recovery methods for Treg isolation, time-consuming and non-cost benefit methods in the conditions of in vitro cell culture experiments for the studies focused on the binding of IL-2 to CD25.
Collapse
Affiliation(s)
- Moein Dehbashi
- Division of Genetics, Department of Biology, Faculty of Sciences, University of Isfahan, Postal Code: 81746-73441, Isfahan, Iran
| | - Zohreh Hojati
- Division of Genetics, Department of Biology, Faculty of Sciences, University of Isfahan, Postal Code: 81746-73441, Isfahan, Iran
| | - Majid Motovali-Bashi
- Division of Genetics, Department of Biology, Faculty of Sciences, University of Isfahan, Postal Code: 81746-73441, Isfahan, Iran
| | - Mazdak Ganjalikhani-Hakemi
- Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Postal Code: 81746-73461, Isfahan, Iran.,Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Akihiro Shimosaka
- Institute of Hematology, Peking Union Medical College, Beijing, China
| |
Collapse
|
2
|
Abstract
Peripheral blood mononuclear cells (PBMCs) have been used as a surrogate model of immune function in studies of multiple medical areas, such as metabolic diseases and immune dysfunction. This chapter describes a standardized technique for blood draw and preparation of PBMCs from whole blood using density gradient centrifugation, followed by cell culture. The main focus is on collection of the PBMC culture media and extraction of cellular proteins in order to provide the materials for biomarker studies.
Collapse
Affiliation(s)
- Hassan Rahmoune
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
| | - Paul C Guest
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
| |
Collapse
|
3
|
System-based proteomic and metabonomic analysis of the Df(16)A +/- mouse identifies potential miR-185 targets and molecular pathway alterations. Mol Psychiatry 2017; 22:384-395. [PMID: 27001617 PMCID: PMC5322275 DOI: 10.1038/mp.2016.27] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Revised: 01/24/2016] [Accepted: 01/28/2016] [Indexed: 12/25/2022]
Abstract
Deletions on chromosome 22q11.2 are a strong genetic risk factor for development of schizophrenia and cognitive dysfunction. We employed shotgun liquid chromatography-mass spectrometry (LC-MS) proteomic and metabonomic profiling approaches on prefrontal cortex (PFC) and hippocampal (HPC) tissue from Df(16)A+/- mice, a model of the 22q11.2 deletion syndrome. Proteomic results were compared with previous transcriptomic profiling studies of the same brain regions. The aim was to investigate how the combined effect of the 22q11.2 deletion and the corresponding miRNA dysregulation affects the cell biology at the systems level. The proteomic brain profiling analysis revealed PFC and HPC changes in various molecular pathways associated with chromatin remodelling and RNA transcription, indicative of an epigenetic component of the 22q11.2DS. Further, alterations in glycolysis/gluconeogenesis, mitochondrial function and lipid biosynthesis were identified. Metabonomic profiling substantiated the proteomic findings by identifying changes in 22q11.2 deletion syndrome (22q11.2DS)-related pathways, such as changes in ceramide phosphoethanolamines, sphingomyelin, carnitines, tyrosine derivates and panthothenic acid. The proteomic findings were confirmed using selected reaction monitoring mass spectrometry, validating decreased levels of several proteins encoded on 22q11.2, increased levels of the computationally predicted putative miR-185 targets UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit (OGT1) and kinesin heavy chain isoform 5A and alterations in the non-miR-185 targets serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform, neurofilament light chain and vesicular glutamate transporter 1. Furthermore, alterations in the proteins associated with mammalian target of rapamycin signalling were detected in the PFC and with glutamatergic signalling in the hippocampus. Based on the proteomic and metabonomic findings, we were able to develop a schematic model summarizing the most prominent molecular network findings in the Df(16)A+/- mouse. Interestingly, the implicated pathways can be linked to one of the most consistent and strongest proteomic candidates, (OGT1), which is a predicted miR-185 target. Our results provide novel insights into system-biological mechanisms associated with the 22q11DS, which may be linked to cognitive dysfunction and an increased risk to develop schizophrenia. Further investigation of these pathways could help to identify novel drug targets for the treatment of schizophrenia.
Collapse
|
4
|
Duque-Guimarães D, Ong TP, de Almeida-Faria J, Guest PC, Ozanne SE. SILAC Mass Spectrometry Profiling: A Psychiatric Disorder Perspective. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 974:289-298. [PMID: 28353248 DOI: 10.1007/978-3-319-52479-5_27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/15/2024]
Abstract
Stable isotope labelling by amino acids in cell culture (SILAC) is a technique that allows proteomic profiling of cells. In this chapter we describe a protocol for the identification and quantification of newly synthesised proteins. The methodology can be applied to any cultured cell system with relevance to schizophrenia, affective disorders and autism spectrum conditions including those addressing responses to pharmacological stimuli.
Collapse
Affiliation(s)
- Daniella Duque-Guimarães
- University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
| | - Thomas Prates Ong
- University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Food Research Center (FoRC) and Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
| | - Juliana de Almeida-Faria
- University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil
| | - Paul C Guest
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária ZeferinoVaz, 13083-862, Campinas, Brazil
| | - Susan E Ozanne
- University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
| |
Collapse
|
5
|
Kroes RA, Nilsson CL. Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants. Curr Neuropharmacol 2017; 15:35-46. [PMID: 26955966 PMCID: PMC5327457 DOI: 10.2174/1570159x14666160309114740] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2015] [Revised: 05/08/2015] [Accepted: 01/30/2016] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Depression affects over 120 million individuals of all ages and is the leading cause of disability worldwide. The lack of objective diagnostic criteria, together with the heterogeneity of the depressive disorder itself, makes it challenging to develop effective therapies. The accumulation of preclinical data over the past 20 years derived from a multitude of models using many divergent approaches, has fueled the resurgence of interest in targeting glutamatergic neurotransmission for the treatment of major depression. OBJECTIVE The emergence of mechanistic studies are advancing our understanding of the molecular underpinnings of depression. While clearly far from complete and conclusive, they offer the potential to lead to the rational design of more specific therapeutic strategies and the development of safer and more effective rapid acting, long lasting antidepressants. METHODS The development of comprehensive omics-based approaches to the dysregulation of synaptic transmission and plasticity that underlies the core pathophysiology of MDD are reviewed to illustrate the fundamental elements. RESULTS This review frames the rationale for the conceptualization of depression as a "pathway disease". As such, it culminates in the call for the development of novel state-of-the-art "-omics approaches" and neurosystems biological techniques necessary to advance our understanding of spatiotemporal interactions associated with targeting glutamatergic-triggered signaling in the CNS. CONCLUSION These technologies will enable the development of novel psychiatric medications specifically targeted to impact specific, critical intracellular networks in a more focused manner and have the potential to offer new dimensions in the area of translational neuropsychiatry.
Collapse
Affiliation(s)
- Roger A. Kroes
- Naurex, Inc., 1801 Maple Street, Evanston, Illinois 60201, United States
| | - Carol L. Nilsson
- Department of Pharmacology & Toxicology, University of Texas Medical Branch, 301 University Blvd, Galveston, Texas, 77555-1074, United States
| |
Collapse
|
6
|
Nascimento JM, Garcia S, Saia-Cereda VM, Santana AG, Brandao-Teles C, Zuccoli GS, Junqueira DG, Reis-de-Oliveira G, Baldasso PA, Cassoli JS, Martins-de-Souza D. Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia. Proteomics Clin Appl 2016; 10:1148-1158. [DOI: 10.1002/prca.201600021] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 06/21/2016] [Accepted: 07/14/2016] [Indexed: 12/20/2022]
Affiliation(s)
- Juliana M. Nascimento
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Sheila Garcia
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Verônica M. Saia-Cereda
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Aline G. Santana
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Caroline Brandao-Teles
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Giuliana S. Zuccoli
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Danielle G. Junqueira
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Guilherme Reis-de-Oliveira
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Paulo A. Baldasso
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Juliana S. Cassoli
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| | - Daniel Martins-de-Souza
- Department of Biochemistry and Tissue Biology; Laboratory of Neuroproteomics; Institute of Biology; University of Campinas (UNICAMP); Campinas São Paulo Brazil
| |
Collapse
|
7
|
de Jesus JR, Pessôa GDS, Sussulini A, Martínez JLC, Arruda MAZ. Proteomics strategies for bipolar disorder evaluation: From sample preparation to validation. J Proteomics 2016; 145:187-196. [PMID: 27113133 DOI: 10.1016/j.jprot.2016.04.034] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 04/19/2016] [Accepted: 04/20/2016] [Indexed: 02/06/2023]
Abstract
Bipolar disorder (BD) is a complex and costly psychiatric disorder, which affects one hundred million people worldwide. Due to its heterogeneity, correct BD diagnosis is still a challenge. In order to overcome this issue, different bioanalytical strategies have been proposed in the literature recently. Among these strategies, proteomic approaches have arisen as some of the most promising in the area. Thus, recent applications suggest protein profiles to further refine the proteome of BD as well as the discovery of novel protein biomarkers to facilitate diagnostics. In this review, the state-of-art of proteomic research in BD is summarized. Furthermore, important aspects of proteomics for understanding of BD, such as sample type and size, sampling, sample preparation, gel-based and gel-free proteomics, proteomic quantitative and protein validation are overviewed.
Collapse
Affiliation(s)
- Jemmyson Romário de Jesus
- Spectrometry, Sample Preparation and Mechanization Group, GEPAM, University of Campinas (UNICAMP), Campinas, Brazil; National Institute of Science and Technology for Bioanalytics, University of Campinas (UNICAMP), Campinas, Brazil; UCIBIO-REQUIMTE, Chemistry Department, Faculty of Sciences and Technology, Universidade Nova de Lisboa, Caparica, Portugal
| | - Gustavo de Souza Pessôa
- Spectrometry, Sample Preparation and Mechanization Group, GEPAM, University of Campinas (UNICAMP), Campinas, Brazil; National Institute of Science and Technology for Bioanalytics, University of Campinas (UNICAMP), Campinas, Brazil
| | - Alessandra Sussulini
- Spectrometry, Sample Preparation and Mechanization Group, GEPAM, University of Campinas (UNICAMP), Campinas, Brazil; National Institute of Science and Technology for Bioanalytics, University of Campinas (UNICAMP), Campinas, Brazil
| | - José Luis Capelo Martínez
- UCIBIO-REQUIMTE, Chemistry Department, Faculty of Sciences and Technology, Universidade Nova de Lisboa, Caparica, Portugal; ProteoMass Scientific Society, MadanPark, Rua dos Inventores s/n, Monte de Caparica, Caparica, Portugal
| | - Marco Aurélio Zezzi Arruda
- Spectrometry, Sample Preparation and Mechanization Group, GEPAM, University of Campinas (UNICAMP), Campinas, Brazil; National Institute of Science and Technology for Bioanalytics, University of Campinas (UNICAMP), Campinas, Brazil.
| |
Collapse
|
8
|
Wesseling H, Gottschalk MG, Bahn S. Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disorders. Int J Neuropsychopharmacol 2014; 18:pyu015. [PMID: 25539505 PMCID: PMC4368865 DOI: 10.1093/ijnp/pyu015] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Extensive research efforts have generated genomic, transcriptomic, proteomic, and functional data hoping to elucidate psychiatric pathophysiology. Selected reaction monitoring, a recently developed targeted proteomic mass spectrometric approach, has made it possible to evaluate previous findings and hypotheses with high sensitivity, reproducibility, and quantitative accuracy. METHODS Here, we have developed a labelled multiplexed selected reaction monitoring assay, comprising 56 proteins previously implicated in the aetiology of major psychiatric disorders, including cell type markers or targets and effectors of known psychopharmacological interventions. We analyzed postmortem anterior prefrontal cortex (Brodmann area 10) tissue of patients diagnosed with schizophrenia (n=22), bipolar disorder (n=23), and major depressive disorder with (n=11) and without (n=11) psychotic features compared with healthy controls (n=22). RESULTS Results agreed with several previous studies, with the finding of alterations of Wnt-signalling and glutamate receptor abundance predominately in bipolar disorder and abnormalities in energy metabolism across the neuropsychiatric disease spectrum. Calcium signalling was predominantly affected in schizophrenia and affective psychosis. Interestingly, we were able to show a decrease of all 4 tested oligodendrocyte specific proteins (MOG, MBP, MYPR, CNPase) in bipolar disorder and to a lesser extent in schizophrenia and affective psychosis. Finally, we provide new evidence linking ankyrin 3 specifically to affective psychosis and the 22q11.2 deletion syndrome-associated protein septin 5 to schizophrenia. CONCLUSIONS Our study highlights the potential of selected reaction monitoring to evaluate the protein abundance levels of candidate markers of neuropsychiatric spectrum disorders, providing a high throughput multiplex platform for validation of putative disease markers and drug targets.
Collapse
Affiliation(s)
| | | | - Sabine Bahn
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB2 1QT, United Kingdom (Wesseling, Gottschalk, and Bahn); Department of Neuroscience, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands (Dr Bahn).H.W. and M.G.G. contributed equally to this work.
| |
Collapse
|
9
|
Gottschalk MG, Wesseling H, Guest PC, Bahn S. Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. Int J Neuropsychopharmacol 2014; 18:pyu019. [PMID: 25609598 PMCID: PMC4368887 DOI: 10.1093/ijnp/pyu019] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2014] [Accepted: 08/28/2014] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Although genetic studies suggest an overlap in risk alleles across the major psychiatric disorders, disease signatures reflecting overlapping symptoms have not been found. Profiling studies have identified candidate protein markers associated with specific disorders of the psychoaffective spectrum, but this has always been done in a selective fashion without accounting for the entire proteome composition of the system under investigation. METHODS Employing an orthogonal system-based proteomic enrichment approach based on label-free liquid chromatography mass spectrometry, we analyzed anterior prefrontal human post-mortem brain tissue of patients affected by schizophrenia (n = 23), bipolar disorder (n = 23), major depressive disorder with (n = 12) and without psychotic features (n = 11), and healthy controls (n = 23). Labeled selected reaction monitoring (SRM) was used to validate these findings on a pathway level. Independent in silico analyses of biological annotations revealed common pathways across the diseases, associated with presynaptic glutamatergic neurotransmission and energy metabolism. We validated the proteomic findings using SRM and confirmed that there were no effects of post-mortem confounders. RESULTS Schizophrenia and affective psychosis were linked to a hypoglutamatergic state and hypofunction of energy metabolism, while bipolar disorder and major depressive disorder were linked to a hyperglutamatergic state and hyperfunction of energy metabolism. CONCLUSIONS These findings support recent investigations, which have focused on the therapeutic potential of glutamatergic modulation in psychotic and affective disorders. We suggest a disease model in which disturbances of the glutamatergic system and ensuing adaptations of neuronal energy metabolism are linked to distinct psychiatric symptom dimensions, delivering novel evidence for targeted treatment approaches.
Collapse
Affiliation(s)
- Michael G Gottschalk
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK (Drs Gottschalk, Wesseling, and Drs Guest and Bahn); Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands (Dr Bahn)
| | - Hendrik Wesseling
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK (Drs Gottschalk, Wesseling, and Drs Guest and Bahn); Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands (Dr Bahn)
| | - Paul C Guest
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK (Drs Gottschalk, Wesseling, and Drs Guest and Bahn); Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands (Dr Bahn)
| | - Sabine Bahn
- Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK (Drs Gottschalk, Wesseling, and Drs Guest and Bahn); Department of Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands (Dr Bahn).
| |
Collapse
|